CLSN News and Press, Celsion Corporation From 02/28/22

Non-dilutive funding further strengthens balance sheet and extends current operating runway through 2024 Additional $3.5 million of unused state NOLs expected to be sold in future years LAWRENCEVILLE, N.J., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (...

Celsion (NASDAQ:CLSN) trades 8.1% down premarket after it plans to implement a consolidation (reverse stock split) of its outstanding shares on the basis of 1-for-15 currently outstanding shares. The new shares will be effective for trading purposes as of Mar.1, 2022 under the ...

LAWRENCEVILLE, N.J., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced that, as previously authorized by its shareholders, the Company is implementing a con...

OVATION 2 Study is Over 75% Enrolled; Full Enrollment Expected by Mid-2022 Novel Gene-Mediated Immunotherapy is Safe and Demonstrates an Acceptable Risk/Benefit When Administered Over a Six-Month Period LAWRENCEVILLE, N.J., Feb. 17...

Preclinical results d emonstrate safe and efficient immune response with v accine development showing promise of neutralizing activity for a range of variants LAWRENCEVILLE, N.J., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a cli...

LAWRENCEVILLE, N.J., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, today announced that it has entered into a securities purchase agreement with certain institut...

Celsion Corporation ’s GEN-1 IL-12 Program in Ad vanced Ovarian Cancer to be Featured in Poster Presentation Chief Science Officer Dr. Khursheed Anwer to Present and Participate in Two Panel Discussions LAWRE...

Celsion Corporation (CLSN) Q3 2021 Earnings Conference Call November 15, 2021, 11:00 AM ET Company Participants Kim Golodetz – HLA Michael Tardugno – Chairman, CEO and President Jeffrey Church – Chief Financial Officer Nicholas Borys – Chief Medical Officer Khurshe...

Celsion (NASDAQ:CLSN): Q3 GAAP EPS of -$0.06 beats by $0.03. Revenue of $0.13M (flat Y/Y) beats by $0.02M. Press Release The Company ended the third quarter of 2021 with $60.6M in cash, investment securities, restricted cash and accrued interest receivable.  Coupled with future sales of ...

Balance Sheet Supports Focus o n Immuno-Oncology and Next-Generation Vaccine Initiative Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation ...